EGFR and breast carcinoma: Our observations that an EGFR/ERBB2 inhibitor (lapatinib and AG825) and a pan‐ERBB inhibitor (AG1478, afatinib and neratinib) treatment induce differential global signaling changes may be of special interest since both an EGFR/ERBB2 inhibitor (lapatinib) and pan‐ERBB inhibitor (neratinib) are currently being used in the clinic as a therapy for HER2+ breast cancer [52].